Pelareorep is a proprietary isolate of a naturally occurring, non-pathogenic double-stranded RNA (dsRNA) virus commonly found in environmental waters, known as reovirus. It is being developed as a first-in-class intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. It activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments.
Pelareorep activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments, including CAR T therapies, bispecific antibodies, and CDK4/6 and PARP inhibitors. We are currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer.
Clinical trials have provided us with a multitude of observations and conclusions thus far regarding the effectiveness of pelareorep in normal cells versus cancerous cells.